Evaluating the Prognostic Significance of Cystatin C Level Variations Pre‐ and Post‐Radiofrequency Catheter Ablation in the Recurrence of Persistent Atrial Fibrillation
Annals of Noninvasive Electrocardiology · 2024-11 · 29 (6)
DOI: 10.1111/anec.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Noninvasive Electrocardiology, online erschienen am 16.10.2024. Verfasst von Yu-Yan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Cystatin C. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou Health Bureau.
Abstract (Originalsprache)
Objective
To investigate the correlation between persistent atrial fibrillation (AF) recurrence and alterations in cystatin C levels pre‐ and post‐radiofrequency catheter ablation (RFCA).
Methods
This study encompassed 114 patients diagnosed with persistent AF. Their serum cystatin C levels were assessed both prior to and 3 months after undergoing an RFCA procedure. The variance in cystatin C levels before and after RFCA is represented as ΔCystatin C. Subsequently, we compared these values between two groups: patients who did not experience a recurrence of AF ( n = 79) and those who did experience a recurrence ( n = 35).
Results
A significant reduction in cystatin C levels post‐RFCA in both groups, with a more pronounced decrease observed in the non‐recurrence group. Moreover, the recurrence group exhibited larger left atrial diameter and volume before RFCA compared to the non‐recurrence group. Cox regression analysis indicated that smaller reductions in serum cystatin C levels and greater left atrial volumes before RFCA were associated with an increased risk of recurrence, after adjusting for covariates. The receiver operating characteristic curve indicated an elevated probability of clinical recurrence of AF post‐RFCA in patients with a cystatin C decline < 0.08 mg/L (AUC 0.64). The Kaplan–Meier survival analysis revealed that patients with a cystatin C decline > 0.08 mg/L exhibited significantly higher rates of remaining free from recurrence following RFCA across a 24‐month follow‐up period (Log‐rank test p = 0.003).
Conclusions
Alterations in ΔCystatin C levels pre and post‐RFCA in the initial phase could independently predict the recurrence of AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
- Department of Cardiology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
ORCID-Profile: Fang-Fang Wang
Förderung
- Changzhou Health Bureau
Zitieren
APA
Zhang, Y. Y., Ge, J. Y., Ji, Y., Zhu, Y., Zhu, Z. Y., & Wang, F. F. (2024). Evaluating the Prognostic Significance of Cystatin C Level Variations Pre‐ and Post‐Radiofrequency Catheter Ablation in the Recurrence of Persistent Atrial Fibrillation. Annals of Noninvasive Electrocardiology, 29(6). https://doi.org/10.1111/anec.70024
Vancouver
Zhang YY, Ge JY, Ji Y, Zhu Y, Zhu ZY, Wang FF. Evaluating the Prognostic Significance of Cystatin C Level Variations Pre‐ and Post‐Radiofrequency Catheter Ablation in the Recurrence of Persistent Atrial Fibrillation. Annals of Noninvasive Electrocardiology. 2024;29(6). doi:10.1111/anec.70024
BibTeX
@article{Zhang2024,
author = {Zhang, Yu-Yan and Ge, Ji-Yong and Ji, Yuan and Zhu, Yi and Zhu, Zhen-Yan and Wang, Fang-Fang},
title = {Evaluating the Prognostic Significance of Cystatin C Level Variations Pre‐ and Post‐Radiofrequency Catheter Ablation in the Recurrence of Persistent Atrial Fibrillation},
journal = {Annals of Noninvasive Electrocardiology},
year = {2024},
volume = {29},
number = {6},
doi = {10.1111/anec.70024}
}
EUVIMED